Integer Holdings Corporation · NYSE:ITGR
Integer — Greatbatch — Merger or Acquisition (April 2007)
14 slides from Integer's merger presentation, Apr 30, 2007
Slide 1: Greatbatch to Acquire Enpath Webcast Presentation
Greatbatch to Acquire Enpath Webcast Presentation April 30, 2007
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the statements made in the presentation whether written or oral may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of Securities Exchange Act of 1934, as amended, and involve a number of
Slide 3: Agenda
Agenda ⑀⍽ Strategic Rationale Thomas Hook ⑀⍽ Financial Highlights Thomas Mazza ⑀⍽ Enpath Company Overview John Hertig ⑀⍽ Key Take-Aways Thomas Hook
Slide 4: Exciting Strategic Opportunity
Exciting Strategic Opportunity ⑀⍽ Expands Product Offering to include single use medical device products - Introducers - Advanced Delivery Catheters - Implantable Stimulation Leads ⑀⍽ Complements Existing CRM Franchise ⑀⍽ Customer and Market Diversification ⑀⍽ Offers Greater Ability to Service Neuro
Slide 5: Agenda
Agenda ⑀⍽ Strategic Rationale Thomas Hook ⑀⍽ Financial Highlights Thomas Mazza ⑀⍽ Enpath Company Overview John Hertig ⑀⍽ Key Take-Aways Thomas Hook
Slide 6: Proposed Offer
Proposed Offer ⑀⍽ Cash Tender Offer ⑀⍽ Price per Share = $14.38 ⑀⍽ Total Equi ty Value = $96.0 MM ⑀⍽ Total Enterprise Value = $102.00 MM ⑀⍽ Estimated Close Mid to Late June 2007 - Subject to Customary Regulatory and Cash Tender Processes
Slide 7: Financial Impact
Financial Impact ⑀⍽ Accelerates Revenue Growth ⑀⍽ Enpath Achieved 2006 Sales of $37 million ⑀⍽ Similar Hi storical Gross Margins 36% - 38% ⑀⍽ Accretion/Dilution • Expected to be Accretive in 2008 • Accretive in 2009 • Subject to final purchase accounting
Slide 8: Combined 2006 Revenue Mix
Combined 2006 Revenue Mix 27% 21% 8% 18% 14% 12% Power Solutions Feedthroughs Enclosures Me d Other Commercial Introducers, Leads & Catheters Sales 150 200 250 300 350 2004 2005 2006 GB Enpath
Slide 9: Agenda
Agenda ⑀⍽ Strategic Rationale Thomas Hook ⑀⍽ Financial Highlights Thomas Mazza ⑀⍽ Enpath Company Overview John Hertig ⑀⍽ Key Take -Aways Thomas Hook
Slide 10: Enpath Company Profile
Enpath Company Profile Business Overview • Develops and manufactures stimulation leads, lead delivery systems, venous vessel introducers, and advanced catheters. • Also serves as a contract product development and manufacturing company for many OEM customers. • Serves the cardiac rhythm management,
Slide 11: Agenda
Agenda ⑀⍽ Strategic Rationale Thomas Hook ⑀⍽ Financial Highlights Thomas Mazza ⑀⍽ Enpath Company Overview John Hertig ⑀⍽ Key Take-Aw ays Thomas Hook
Slide 12: Key Take-Aways
Key Take-Aways ⑀⍽ Diversifies Customers and Markets ⑀⍽ S ynergistic RD&E activities ⑀⍽ Accelerates Revenue Growth Rate ⑀⍽ Offers greater ability to service the growing Neurostimulation and CRM markets
Slide 13: Contact Information
Contact Information Tony Borowicz Treasurer & Director of Investor Relations Grea tbatch, Inc. 9645 Wehrle Drive Clarence, NY 14031 ⑀⍽ Telephone 716.759.5809 ⑀⍽ Fax 716.759.5614 ⑀⍽ E-Mail tborowicz@greatbatch.com Contact Information
Slide 14: Greatbatch to Acquire Enpath Webcast Presentation
Greatbatch to Acquire Enpath Webcast Presentation April 30, 2007